CIDP

16 registered clinical trials studyying CIDP — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP NCT07091630	argenx	Phase 3
Recruiting	A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP NCT06920004	argenx	Phase 3
Recruiting	Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study NCT07264426	argenx	—
Not Yet Recruiting	Vitaccess Real CIDP Registry NCT07006597	Vitaccess Ltd	—
Recruiting	Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy NCT06714838	Amsterdam University Medical Center (UMC), Location Academic Medical Center (AMC)	Phase 3
Recruiting	Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CI NCT04881682	University of Ulm	Phase 2
Terminated	Validation of Cutaneous Nerve Demyelination in Diagnosis and Treatment of CIDP NCT05614128	Vanderbilt University Medical Center	—
Completed	Electronic Monitoring of Disease Activity in Patients With Chronic Inflammatory Demyelinating Polyneuropathy NCT05723848	Heinrich-Heine University, Duesseldorf	—
Recruiting	IVIG vs SCIG in CIDP NCT05584631	Rutgers, The State University of New Jersey	Phase 1
Recruiting	Biorepository and Registry for Plasma Exchange Patients NCT05004493	Charles M Knudson	—
Unknown	Biomarkers in Polyradiculoneuropathies NCT04249752	University Hospital, Montpellier	—
Unknown	Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation NCT03801135	University Medical Centre Ljubljana	N/A
Completed	Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradicul NCT02629796	Fondation Ophtalmologique Adolphe de Rothschild	—
Unknown	Change of Nerve Conduction Properties in IVIg Dependent Neuropathies NCT01655394	University of Cologne	—
Completed	Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy NCT00962429	Oregon Health and Science University	Phase 2
Available	Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy NCT04777734	argenx	—